We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
Read MoreHide Full Article
Shares of Immunovant, Inc. (IMVT - Free Report) have rallied 27% in the past three months against the industry’s decrease of 4.1%.
The company has made good progress during this period with the development of its lead pipeline candidate, batoclimab (formerly IMVT-1401), which is being developed for the treatment of several autoimmune diseases.
Batoclimab is a fully human, monoclonal antibody that selectively binds to and inhibits neonatal fragment crystallizable receptor (FcRn). The candidate is being developed as a subcutaneous injection for the treatment of myasthenia gravis (“MG”), warm autoimmune hemolytic anemia (“WAIHA”) and thyroid eye disease (“TED”). IMVT is making rapid progress in the batoclimab’s development this year.
Image Source: Zacks Investment Research
In June 2022, Immunovant initiated a pivotal study evaluating batoclimab for the treatment of MG. Top-line data from the same is expected in the second half of 2024.
During the same time, the company also achieved alignment with the FDA’s Division of Ophthalmology to initiate two phase III studies evaluating batoclimab for treating TED. Both studies are expected to begin in the second half of 2022. Top-line data from both are expected in the first half of 2025.
The company also plans to initiate a placebo-controlled study on batoclimab as a treatment for WAIHA, contingent on discussions with the hematology division of the FDA, which is expected to take place later in 2022.
IMVT plans to evaluate potential new indications for batoclimab and has plans to announce two new indications later this week.
We note that batoclimab, if approved, may face competition from other approved drugs for TED, WAIHA or MG.
Horizon Therapeutics’ Tepezza, an anti-IGF-1R antibody, is approved for the treatment of TED.
Horizon is evaluating Tepezza in several label expansion studies. The drug has been one of the key top-line drivers for HZNP since its approval.
In the absence of a marketed drug, the successful development of batoclimab remains the main focus of Immunovant. There is only one candidate in development in its pipeline. Batoclimab is still in late-stage development and is still a few years away from commercialization. Any developmental setback for batoclimab will be a major setback for the company, leaving an adverse impact on its shares.
Achilles Therapeutics’ loss per share estimates narrowed 6.4% for 2022 and 9.6% for 2023 in the past 60 days.
Earnings of Achilles Therapeutics surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ACHL delivered an earnings surprise of 12.45%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 43.2% for 2022 and 31.8% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
Shares of Immunovant, Inc. (IMVT - Free Report) have rallied 27% in the past three months against the industry’s decrease of 4.1%.
The company has made good progress during this period with the development of its lead pipeline candidate, batoclimab (formerly IMVT-1401), which is being developed for the treatment of several autoimmune diseases.
Batoclimab is a fully human, monoclonal antibody that selectively binds to and inhibits neonatal fragment crystallizable receptor (FcRn). The candidate is being developed as a subcutaneous injection for the treatment of myasthenia gravis (“MG”), warm autoimmune hemolytic anemia (“WAIHA”) and thyroid eye disease (“TED”). IMVT is making rapid progress in the batoclimab’s development this year.
Image Source: Zacks Investment Research
In June 2022, Immunovant initiated a pivotal study evaluating batoclimab for the treatment of MG. Top-line data from the same is expected in the second half of 2024.
During the same time, the company also achieved alignment with the FDA’s Division of Ophthalmology to initiate two phase III studies evaluating batoclimab for treating TED. Both studies are expected to begin in the second half of 2022. Top-line data from both are expected in the first half of 2025.
The company also plans to initiate a placebo-controlled study on batoclimab as a treatment for WAIHA, contingent on discussions with the hematology division of the FDA, which is expected to take place later in 2022.
IMVT plans to evaluate potential new indications for batoclimab and has plans to announce two new indications later this week.
We note that batoclimab, if approved, may face competition from other approved drugs for TED, WAIHA or MG.
Horizon Therapeutics’ Tepezza, an anti-IGF-1R antibody, is approved for the treatment of TED.
Horizon is evaluating Tepezza in several label expansion studies. The drug has been one of the key top-line drivers for HZNP since its approval.
In the absence of a marketed drug, the successful development of batoclimab remains the main focus of Immunovant. There is only one candidate in development in its pipeline. Batoclimab is still in late-stage development and is still a few years away from commercialization. Any developmental setback for batoclimab will be a major setback for the company, leaving an adverse impact on its shares.
Immunovant, Inc. Price and Consensus
Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote
Zacks Rank & Stocks to Consider
Immunovant currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Achilles Therapeutics plc (ACHL - Free Report) and Atara Biotherapeutics, Inc. (ATRA - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Achilles Therapeutics’ loss per share estimates narrowed 6.4% for 2022 and 9.6% for 2023 in the past 60 days.
Earnings of Achilles Therapeutics surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ACHL delivered an earnings surprise of 12.45%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 43.2% for 2022 and 31.8% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.